Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Glucagon for Insulin Induced Hypoglycemia
NCT01994746Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Primary completion
- Jan 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glucagon in hypoglycemia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir at 30 months. Started Nov 2013; status: completed.
02
Drugs
glucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT01994746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994746.